REGN
Regeneron Pharmaceuticals
NASDAQ · Biotechnology
$785.51
+18.88 (+2.46%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 13.96B | 13.22B | 58.28B | 59.21B | 47.24B |
| Net Income | 4.38B | 3.74B | 1.54B | 1.62B | 1.36B |
| EPS | — | — | — | — | — |
| Profit Margin | 31.4% | 29.8% | 2.7% | 2.7% | 2.9% |
| Rev Growth | +5.6% | +5.6% | +14.8% | +14.6% | -9.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 3.31B | 3.31B | 7.16B | 8.72B | 6.67B |
| Total Equity | 38.21B | 38.21B | 41.65B | 41.22B | 41.73B |
| D/E Ratio | 0.09 | 0.09 | 0.17 | 0.21 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 4.21B | 3.79B | 2.09B | 2.06B | 1.48B |
| Free Cash Flow | — | — | 742.46M | 732.77M | 925.95M |